Beta Bionics Q3 Sales Up 30% to $35.5M; Guidance Raised, 3D Intelligence 510(k) Withdrawn
BBNX has more than doubled off its 52-week low of $8.8.
Summary
Beta Bionics grew Q3 net sales 30% to $35.5M and nudged full-year guidance to $124M-$126M, but withdrew its 3D Intelligence 510(k) and now plans a revised submission in mid-Q4 2026, delaying the next-gen algorithm launch.
Key Events · Earnings and Guidance · BBNX
-
Q3 Sales Up 30% to $35.5M
Net sales rose to $35.5 million from $27.3 million a year ago, with the PBP channel up 118% to $13.6 million and DME up 4% to $21.9 million.
-
Operating Loss Widens Sharply
Loss from operations was $26.6 million, or negative 75% of sales, versus $17.0 million (negative 63%) a year ago; adjusted EBITDA was negative $18.9 million.
-
3D Intelligence 510(k) Withdrawn
After FDA interactions the company withdrew its 510(k) for 3D Intelligence and will submit a revised application with additional simulator validation data in mid-Q4 2026.
-
Guidance Narrowed and Raised
Full-year 2026 revenue guidance is now approximately $124M-$126M (previously $121M-$126M), including a potential Q4 deferral of up to $8.5 million as buyers await Mint.
Analysis · BBNX · Industrial Applications And Services
Revenue growth of 30% and a gross margin up 179 basis points to 57.3% are solid, but the operating loss widened to $26.6M (negative 75% of sales) from $17.0M a year ago as sales and marketing spend nearly doubled. More consequential is the withdrawal of the 3D Intelligence 510(k) after FDA interactions: the next-generation algorithm now needs a revised submission in mid-Q4 2026, pushing the iLet 3D/Mint 3D launch into the first half of 2027 at the earliest. Guidance was narrowed and raised to $124M-$126M, yet management explicitly bakes in up to $8.5M of Q4 revenue deferral as prospective iLet buyers wait for Mint, which launches in Q1 2027. With $373.6M in cash after the September offering, funding is not the issue; execution on the regulatory resubmission and the Mint launch is.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBNX was trading at $20.89 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $8.80 to $32.71. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.